Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00498342 · ClinicalTrials.gov registry record · NA

The Effect of Administration on N-Acetylcysteine on Serum Creatinine Levels in Patients With Chronic Kidney Disease

A NA study of Chronic Kidney Disease, sponsored by University of Vermont.

Completed
Registry status
NA
Development phase
1
Study location

NCT00498342 is a NA study of Chronic Kidney Disease that has completed, run by University of Vermont. The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00498342, a NA study of Chronic Kidney Disease, has completed, sponsored by University of Vermont.

COMPLETED
Registry status
NA
Development phase
1
Study location

Study Summary

Primary outcome: Serum creatinine change at 4 hours and 48 hours following 4 doses of N-acetylcysteine (total 4800 mg) compared to baseline serum creatinine. Secondary outcome: Serum Cystatin C change at 4 hours and 48 hours post 4 doses of N-acetylcysteine compared to baseline serum Cystatin C.

Conditions Studied

Interventions

  • DRUG N-acetylcysteine

Study Locations (1)

Vermont

  • University of Vermont /Fletcher Allen Health Care, Inc. - Burlington

Trial Details

FieldValue
Start Date 2007-06
Est. Completion 2008-02
Phase NA

Sponsor

University of Vermont

162 total trials

What the Registry Record Tells You About NCT00498342

The ClinicalTrials.gov registry entry for NCT00498342 describes a study currently listed as completed, categorized as NA. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is University of Vermont, which has 162 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Chronic Kidney Disease appearing as the primary indexed condition, and to 1 intervention - of which N-acetylcysteine is the first listed.

NCT00498342 reports 1 study location spanning 1 distinct geographic area - top geographies include Vermont.

Frequently Asked Questions

What is clinical trial NCT00498342 about?

NCT00498342 is a clinical study titled "The Effect of Administration on N-Acetylcysteine on Serum Creatinine Levels in Patients With Chronic Kidney Disease". Primary outcome: Serum creatinine change at 4 hours and 48 hours following 4 doses of N-acetylcysteine (total 4800 mg) compared to baseline serum creatinine. Secondary outcome: Serum Cystatin C change at 4 hours and 48 hours post 4 doses of N-acetylcysteine compared to baseline serum Cystatin C.

What is the current status of trial NCT00498342?

This trial is currently completed. It is a NA study. The study started on 2007-06. Estimated completion is 2008-02.

What conditions does trial NCT00498342 study?

This clinical trial studies the following conditions: Chronic Kidney Disease.

What interventions are being tested in trial NCT00498342?

The interventions under investigation include: N-acetylcysteine (DRUG).

Who is sponsoring clinical trial NCT00498342?

This trial is sponsored by University of Vermont, which has 162 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00498342 being conducted?

This trial has 1 study location across Vermont. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.